NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical...
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over...
IBB looks to be in a Wyckoff Redistribution phase, with UTAD emerging currently. On a larger time frame, looks as though a weekly H&S patter forming with the re-distribution section acting as the right shoulder. My price target is $57, in line with the 1.618 fib extension.
IGMS is down about 70% YTD with no end is sight as the cash burn is greater than the analyst's estimates.On the 2H chart, the midline of the Bollinger Bands has had a persistent negative slope. Overall, IGMS is very shortable if shares can be found at a low cost. I will watch for a correction of the upgoing price toward the middle of the Bollinger Bands ...
SLN has appreciated 70% in the past month largly on the strength of an earnings beat. Unlike many small cap biotechnology companies, SLN is actually making money and beating analyst's estimates. On the 3O minute chart, price is just below the POC line of the near term volume profile and sitting on the dynamic support of a VWAP line. Strength lines are above...
FULC a biotechnology firm with a mixed earnings report early in the month just printed a big move and then stalled at the NY lunch - hour and faded. Will the fade continue or will there be an upward continuation? The 15 -minute chart seems to suggest a downtrend: 1, The volume profile shows heavy trading at the top. This could be short sellers...
NKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be...
BIOL had a triple top in late July so this is a logical long target at 8,0, With earnings in less than two days, volumes above the mean in the past couple of days and a decent price-volume product trend coupled with a Price Monetum Oscillator without any signs of topping out in a momentum stall or fade. I see this as a long pre-earnings play with about 12%...
AADI has earnings in two day. On the 30 minute chart, it is significantly below the highs of May and June where it was in a wide ranged consolidation. After that in July price trended down along the support of the second lower VWAP line into a reversal on August 1 shich also ascended the VWAP lines. Upcoming earnings are in two days on the 9th. Prior two...
for the next phase of the price action - the details are on the chart. Please comment if you would like further details.
AMRX is a penny biotechnology stock with earnings out on the Friday the 4th. As you can see on the 15 minute chart, it took off out of consolidation on Wednesday afternoon in a burst of price volume and volatility into an ascending parallel channel. I will buy the stock in the pre-market attempting to exploit the momentum going into earnings. If there is a...
LABU is gearing up for a massive rally before it dumps. I have seen this chart pattern alot and I am looking forward to see how it plays out. Not investment advice, please do your DD.
FLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes...
EBS is a small biotechnology company whose forte is the clean processing and manufacturing facility that the FDA requires for certain bioprocessing to be certified for delivery of products to end-user patients. It is not a research facility like the one in China that accidentally released COVID and the global impact will be likely felt for another decade. ...
FULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10%...
VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing...
VRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed...
BlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings...